Aquinox Pharma pulls in $15M for cancer and inflammation
Aquinox Pharmaceuticals, a Vancouver drug developer, raised $14.5 million in a first funding round. Ventures West Capital led the round, joined by Johnson & Johnson Development Corp., Baker Brothers Investments and BC Advantage Funds.
Aquinox is developing drugs that inhibit a newly discovered enzyme called SHIP (for more detail, see here) that appears to play an important role in blood cancers and inflammatory diseases. The company’s lead drug candidate, AQX-MN100, is still in animal testing.
Next Story: Ron Conway: Third-rate VCs are paying off entrepreneurs
Previous Story: Roundup: Geomas' geo-search patent, Google's privacy, YouTube filters, and more
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
